Diabetes Drugs Affect Tiny Blood Vessel Particles Differently: Liraglutide vs. Empagliflozin vs. Gliclazide | Research

The takeaway

A pilot RCT found that liraglutide, empagliflozin, and gliclazide differentially modulate circulating extracellular vesicle subpopulations in type 2 diabetes.

Drug-specific EV changes
Liraglutide, empagliflozin, and gliclazide each produce distinct extracellular vesicle profile modifications

What the researchers found

Liraglutide, empagliflozin, and gliclazide produced distinct changes in circulating extracellular vesicle subpopulations in T2D, potentially reflecting different vascular effects.

Why it matters

EVs may explain how different diabetes drugs protect (or fail to protect) blood vessels. This could eventually guide drug selection based on vascular biomarkers.

How the study worked

Single-center pilot randomized controlled trial; 60 T2DM patients + 20 healthy controls; EV concentration and subpopulation profiling pre- and post-treatment.

What this study cannot tell us

Pilot study with small sample per arm; short-term treatment; EV measurement methodology still being standardized; clinical significance of EV changes uncertain.

How to read the evidence

Pilot RCT — randomized but small, hypothesis-generating rather than definitive.

When this study was published

Published 2026 in Journal of Diabetes and Its Complications.

The bigger picture

EV profiling could become a tool for monitoring vascular health in diabetes and selecting therapies based on their specific effects on blood vessel biology.

Questions still open

Do EV profile changes predict long-term cardiovascular outcomes?
Can EV monitoring guide personalized diabetes medication selection?

Common questions

What are extracellular vesicles in diabetes?

EVs are tiny particles shed by blood vessel cells and other cells into the bloodstream. In diabetes, elevated EV levels indicate blood vessel stress, and different medications affect these levels differently.

Could blood tests guide which diabetes drug to use?

Potentially — if EV profiles predict how well a drug protects blood vessels, they could eventually help doctors choose the best medication for each patient's vascular health needs.

Read the original research

Modulation of circulating extracellular vesicles by antihyperglycemic therapies: A pilot randomized controlled trial.

Journal of diabetes and its complications, 40(3), 109273

View on PubMed ↗Publisher’s paper ↗

Citation

Baldassarre, Maria Pompea Antonia; Carrieri, Federica; Coluzzi, Sara; D'Ascanio, Francesca; Di Pietrantonio, Nadia; Centorame, Giorgia; Pipino, Caterina; Lanuti, Paola; Consoli, Agostino; Formoso, Gloria. (2026). Modulation of circulating extracellular vesicles by antihyperglycemic therapies: A pilot randomized controlled trial.. Journal of diabetes and its complications, 40(3), 109273. https://doi.org/10.1016/j.jdiacomp.2026.109273